SEC Filings

8-K
PERNIX THERAPEUTICS HOLDINGS, INC. filed this Form 8-K on 06/26/2019
Entire Document
 

 

In re: Pernix Sleep, Inc. et al. Case No. 19-10323 (CSS)
Debtors Reporting Period: April 1, 2019 -April 30, 2019

MOR – la
Schedule of Disbursements by Debtor Entity(1)
For the Period: April 1, 2019 -April 30, 2019
(Unaudited)

 

$ USD '000s
Debtors
Case Number April 1, 2019 – April 30, 2019 Cumulative
Since Filing
Pernix Therapeutics, LLC 19-10329 $(26,708) $(42,332)
Cypress Pharmaceuticals, Inc. 19-10330  (5,952)  (6,911)
Pernix Ireland Limited 19-10325  (55)  (56)
Pernix Ireland Pain Designated Activity Company 19-10327  (110)  (262)
Pernix Therapeutics Holdings, Inc.(2) 19-10324  (5)  (14,534)
Gaine, Inc. 19-10335  -   - 
Hawthorn Pharmaceuticals, Inc. 19-10336  -   - 
Macoven Pharmaceuticals, L.L.C. 19-10334  -   - 
Pernix Holdco 1, LLC 19-10331  -   - 
Pernix Holdco 2, LLC 19-10332  -   - 
Pernix Holdco 3, LLC 19-10326  -   - 
Pernix Manufacturing, LLC 19-10328  -   - 
Pernix Sleep, Inc. 19-10323  -   - 
Respicopea, Inc. 19-10333  -   - 
Total   $(32,830) $(64,095)

 

Notes:

(1) The Schedule of Disbursements is presented on a book basis. The five entities included on the schedule represent all disbursements of the Debtors. The other remaining nine Debtor entities do not make disbursements. 

(2) Pernix Therapeutics Holdings, Inc. disbursements includes the payoff of the pre-petition ABL and interest totaling $14,528,717.

 

7